vy7523
·Code: VY7523
vy7523: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Voyager Therapeutics, Inc. (VYGR) | Phase 1/Phase 2 |
Clinical Trials (1)
VY7523-102: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Ascending Intravenous Doses of VY7523 in Participants With Early Alzheimer's Disease
Frequently asked questions
Who is developing vy7523?
vy7523 is being developed by Voyager Therapeutics, Inc..
How many clinical trials involve vy7523?
BioSniper tracks 1 clinical trial involving vy7523.
Get deeper analysis on vy7523
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis